A PYMNTS Company

Singapore: Diagnostics service merger hits merger review snafu

By  |  November 27, 2014

The Competition Commission of Singapore has reportedly not yet approved of the proposed acquisition of diagnostics service provider RadLink-Asia, instead raiding competition concerns over the deal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Reports say the CCS issued a statement highlighting potential harms to competition in the diagnostics services industry following the deal. RadLink-Asia would be acquired by Parkway Holdings from its current owner, India-based Fortis Healthcare.

    The acquisition was agreed upon last September for $108.6 million.

    But both Parkway and RadLink operate in the radiopharmaceutical supply industry, as well as other markets, leading the CCS to open a Phase 2 review of the transaction. The CCS has additionally asked the companies for more information on the merger.

    Full content: VCCircle

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.